Risk factors for low-level viremia in tenofovir disoproxil fumarate-treated chronic hepatitis B patients with advanced hepatic fibrosis/compensated cirrhosis
World Journal of Gastroenterology · 21.08.2026 · 32 (31)
DOI: 10.3748/wjg.119706 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Gastroenterology, online erschienen am 21.08.2026. Verfasst von Run-Ling Zhang und 6 weiteren Autor:innen. Die Arbeit nennt 32 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND Patients diagnosed with chronic hepatitis B (CHB) complicated by advanced hepatic fibrosis/compensated cirrhosis face a significant risk of disease progression. Despite first-line nucleos(t)ide analog therapy, some patients continues to exhibit low-level viremia (LLV). Furthermore, LLV is closely associated with accelerated liver fibrosis progression and a higher likelihood of hepatocellular carcinoma. Clinical studies on accurate prognostic indicators for LLV in this patient group are still comparatively rare. AIM To identify the high-risk factors linked to the occurrence of LLV among CHB patients with advanced hepatic fibrosis/compensated cirrhosis. METHODS This retrospective study enrolled 141 CHB patients with advanced hepatic fibrosis/compensated cirrhosis who received tenofovir disoproxil fumarate (TDF). Patients were allocated into two groups according to their virological response at week 48 after treatment initiation: LLV, defined as hepatitis B virus (HBV) DNA levels of 20-2000 IU/mL, and complete virological response (CVR), defined as HBV DNA levels below 20 IU/mL. Univariate and multivariate logistic regression analysis were carried out to determine risk factors for LLV development. RESULTS A total of 141 patients were included in this study, among whom 17.0% (24/141) developed LLV. Significant differences were identified between the LLV and CVR groups regarding baseline HBV DNA, HBV RNA, hepatitis B e antigen positivity, HBV DNA ≥ 5.0 Log10 IU/mL, 6.0 Log10 IU/mL, 7.0 Log10 IU/mL, HBV RNA ≥ 5.0 Log10 copies/mL, and baseline alpha-fetoprotein. Multivariate logistic regression confirmed that that HBV DNA ≥ 7.0 Log10 IU/mL (OR = 18.824, 95%CI: 1.608-220.404, P = 0.019) at baseline was associated with the occurrence of LLV. CONCLUSION In TDF-treated CHB with advanced hepatic fibrosis/compensated liver cirrhosis, HBV DNA ≥ 7.0 Log10 IU/mL is a high-risk factor associated with LLV.
Zitieren
APA
Zhang, R., Zhang, H., Jia, Y., Wang, Z., Liu, F., Chen, H., & Rao, H. (2026). Risk factors for low-level viremia in tenofovir disoproxil fumarate-treated chronic hepatitis B patients with advanced hepatic fibrosis/compensated cirrhosis. World Journal of Gastroenterology, 32(31). https://doi.org/10.3748/wjg.119706
Vancouver
Zhang R, Zhang H, Jia Y, Wang Z, Liu F, Chen H, et al. Risk factors for low-level viremia in tenofovir disoproxil fumarate-treated chronic hepatitis B patients with advanced hepatic fibrosis/compensated cirrhosis. World Journal of Gastroenterology. 2026;32(31). doi:10.3748/wjg.119706
BibTeX
@article{Zhang2026,
author = {Zhang, Run-Ling and Zhang, Hai-Ying and Jia, Yu-Yuan and Wang, Zhen-Yu and Liu, Feng and Chen, Hong-Song and Rao, Hui-Ying},
title = {Risk factors for low-level viremia in tenofovir disoproxil fumarate-treated chronic hepatitis B patients with advanced hepatic fibrosis/compensated cirrhosis},
journal = {World Journal of Gastroenterology},
year = {2026},
volume = {32},
number = {31},
doi = {10.3748/wjg.119706}
}
EUVIMED